It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-20 04:45:00 Source:entertainmentViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
You may also like
- Grimes screams on stage after having 'major technical difficulties' during chaotic set at Coachella
- Bilbao end 40
- What does science say about the ingredients in functional beverages?
- Tourists visit Yuanmingyuan Park in Beijing
- Paris Olympics flame to be lit with elan at Greek cradle of ancient games
- Kipyegon and Duplantis set to star in Xiamen
- LeBron James becomes first player to score 40000 points
- Palestinian death toll in Gaza rises to 32,490: ministry
- China unveils plan to promote trade